Enhanced antitumor efficacy by combination treatment with a human umbilical vein endothelial cell vaccine and a tumor cell lysate-based vaccine

Tumor Biology

Volumn 34, Issue 5, 2013, Pages 3173-3182

  Xu, Maolei ^a   Zhou, Ling ^a   Zhang, Peng ^a   Lu, Yong ^a   Ge, Chiyu ^a   Yao, Wenjun ^a   Xing, Yun ^a   Xiao, Wen ^a   Dong, Yuankai ^a   Wu, Jie ^a   Cao, Rongyue ^a   Li, Taiming ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Cancer cell vaccine; Hepatocellular carcinoma immunotherapy; Human umbilical vein endothelial cell

Indexed keywords

EID: 84885423139     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0887-8     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol: Off J Am Soc Clin Oncol. 2005;23(13):2892-9. doi: 10.1200/jco.2005.03.196.
3. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698-711. doi: 10.1093/jnci/djn134.
4. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25(27):3866-84. doi: 10.1038/sj.onc.1209550.
5. Cao DY, Yang JY, Yue SQ, Tao KS, Song ZS, Wang DS, et al. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma. Cell Immunol. 2009;259(1):13-20. doi: 10.1016/j.cellimm.2009.05.007.
6. Huang L, Ohno T. Protective antitumor immunity induced by fixed tumor cells in combination with adjuvant in a murine hepatoma model. Cancer Lett. 2003;202(2):153-9.
7. Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, Lee Y, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol. 2012;41(5):1601-9. doi: 10.3892/ijo.2012.1626.
8. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer. 1996;32A(14):2451-60.
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-6. doi: 10.1056/NEJM197111182852108.
10. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4-6. doi: 10.1093/jnci/82.1.4.
11. Chen XY, Zhang W, Wu S, Bi F, Su YJ, Tan XY, et al. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin Cancer Res: Off J Am Assoc Cancer Res. 2006;12(19):5834-40. doi: 10.1158/1078-0432. ccr-06-1105.
12. Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci. 2004;95(1):85-90.
13. Okaji Y, Tsuno NH, Tanaka M, Yoneyama S, Matsuhashi M, Kitayama J, et al. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer. 2008;44(3):383-90. doi: 10.1016/j.ejca.2007.10.018.
14. Tanaka M, Tsuno NH, Fujii T, Todo T, Saito N, Takahashi K. Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma. Cancer Sci. 2013;104(2):200-5. doi: 10.1111/cas.12055.
15. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 2000;6(10):1160-6. doi: 10.1038/80506.
16. Xu M, Xing Y, Zhou L, Yang X, Yao W, Xiao W, et al. Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013. doi: 10.1007/s13277-012-0616-8.
17. Okaji Y, Tsuno NH, Saito S, Yoneyama S, Tanaka M, Nagawa H, et al. Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2006;32(4):363-70. doi: 10.1016/j.ejso.2006.01.016.
18. Bukawa H, Sekigawa K, Hamajima K, Fukushima J, Yamada Y, Kiyono H, et al. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat Med. 1995;1(7):681-5.
19. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol. 1999;17(4):343-8. doi: 10.1038/7895.
20. Yang J, Zhang Y, Wang H, Gao Z, Wang Z, Liu B, et al. Vaccination with the repeat beta-hCG C-terminal peptide carried by heat shock protein-65 (HSP65) for inducing antitumor effects. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2012. doi: 10.1007/s13277-012-0437-9.
21. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res. 2006;312(5):594-607. doi: 10.1016/j.yexcr.2005.11.015.
22. Chougule MB, Patel A, Sachdeva P, Jackson T, Singh M. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer. PLoS One. 2011;6(11):e27394. doi: 10.1371/journal.pone.0027394.
23. Stopeck AT, Unger JM, Rimsza LM, Leblanc M, Farnsworth B, Iannone M, et al. A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood. 2012. doi: 10.1182/blood-2012-04-423079.
24. Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A, et al. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol. 2012. doi: 10.1007/s00280-012-1911-1.
25. Ishii Y, Sakamoto T, Ito R, Yanaga K. Anti-angiogenic therapy on hepatocellular carcinoma development and progression. J Surg Res. 2010;158(1):69-76. doi: 10.1016/j.jss.2008.09.015.
26. Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst. 2000;92(2):143-7.